Levonorgestrel intrauterine - Allergan

Drug Profile

Levonorgestrel intrauterine - Allergan

Alternative Names: Levosert; LILETTA; LNG20

Latest Information Update: 27 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mithra Pharmaceuticals
  • Developer Allergan
  • Class Hormonal replacements; Norpregnanes; Oral contraceptives; Small molecules
  • Mechanism of Action Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Menorrhagia; Pregnancy

Most Recent Events

  • 22 Feb 2018 The US FDA accepts sNDA for extension of use of levonorgestrel intrauterine for up to five years for Contraception in USA
  • 07 Aug 2017 FDA approves sNDA for extension of use of levonorgestrel intrauterine for up to four years for Contraception in USA
  • 15 Feb 2017 Medicines360 and Allergan announce partnership with 340-B eligible health centers in Puerto Rico and Florida for supply of levonorgesterol intrauterine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top